Mental health studies

Molecular Genetics of Adverse Drug Reactions: From candidate genes to genome wide

The purpose of this study is to identify patients with different types of adverse drug reactions as a result of taking antipsychotic medication (Clozapine). Researchers are aiming to use DNA obtained from blood or saliva samples to identify genetic factors determining these adverse reactions and to develop genetic tests which can help in predicting individual sensitivity in the future.

Dr Lawrence Ratna

Building Resilience and Recovery through Enhancing Cognition and quality of Life in the early Psychoses (ECLIPSE) - Study 9: Implementation of Remediation into Early Intervention Services

Schizophrenia and delusional disorders involve a wide range of symptoms, including seeing or hearing things that are not there (hallucinations), having beliefs that do not reflect reality (delusions). These symptoms can be very difficult for patients to deal with, often affecting the way they live their lives and their ability to work. A new psychological treatment known as cognitive remediation (CRT) can improve both cognitive and functional recovery, including social relationships, work and studying. The ideal time to provide CRT is when a patient is being seen by the Early Intervention Services (for young people experiencing psychosis for the first time, and during the first three years following this first episode) as it is well known that it is more effective for younger people and may have larger effects on functioning if the intervention happens at the earliest opportunity. Thus this study aims to investigate whether it is feasible to incorporate CRT into routine NHS Early Intervention Services (EIS) for treating non-affective psychosis.

Ms Tjasa Velikonja

PPIP

An observational cohort study, recruiting patients with acute Psychosis symptoms to identify the prevalence of antibodies to neuronal membrane targets. This four year study includes a pilot.

BENEMIN

Recent research at the University of Manchester has found that recovery from early psychosis is improved by taking a well-known antibiotic called minocycline. The aim of this research is to confirm the benefit of minocycline and to understand how it works using brain imaging and computer tasks. The study is funded by the NHS National Institute of Health Research (NIHR) and Medical Research Council (MRC) of the United Kingdom.

OPAINT

This trial is a Randomised, double-blind, placebo controlled trial evaluating the effects of naloxone hydrochloride nasal spray on eating behaviours in bulimianervosa. Naloxone hydrochloride nasal spray is being developed by Opiant Pharmaceuticals (Santa Monica, USA), the Sponsor of the study, for treating eating behaviours in patients with bulimia nervosa. The aim of this study is to find out how well the nasal spray affects binging and eating behaviours including risk taking and control of risks in patient with bulimia nervosa.  The study will also see how dosing once or once or twice a day with the study medication or placebo over an 8-week period affects eating behaviours in patients with bulimia nervosa.The study will also look at the safety of the nasal spray in patients with bulimia nervosa.

INTER-STAARS

The study is specifically aimed to test the efficacy of early attentional control training in babies with a parent and/or an older sibling with attention deficit disorders

Research into Antipsychotic Discontinuation and Reduction- Recruitment Study (RADAR)

A preparatory to compare a gradual strategy of antipsychotic reduction (antipsychotic minimisation) with maintenance (continuous) treatment in people with schizophrenia or recurrent psychotic episodes. The current study aims to assess the proportion of people with recurrent psychosis or schizophrenia who would be eligible and willing to enter a controlled trial such as the one proposed.

Dr Joanna Moncrieff

PANDA

This study is designed to refine the indications for the use of antidepressants in people with depression. The aim is to carry out a double – blind randomised placebo – controlled trial in order to investigate the severity and duration of depressive symptoms that are associated with a clinically important response to sertraline in people with depression.

Dr Glyn Lewis

DNA variation

The study is analysing genetic differences in those over 18s with Learning Disabilities and mental health problems. To identify genes which influence treatment response and prognosis.

Dr Gita Prabhu

BPD/ASPB

Probing Social Exchanges – A Computational Neuroscience Approach to the Understanding of Borderline and Anti-Social Personality Disorder aiming to identify shared and distinct computational processes and their underlying neural correlates.

Sudden Death in Psychiatric in-patients and the Relationship with Psychotropic Drugs

To establish the number and rate of sudden death in psychiatric inpatients and carry out a case-control study identifying independent risk factors for sudden death in this population.

Dr Alyson Williams

 

BEH-NON PORTFOLIO STUDIES 

2015

non-portfolio studies 

Olivia Patsalos, Clinical Studies Officer Olivia.patsalos@nhs.net

Lisa Russell, Clinical Research Officer. Tel: 07872 850370; Email: lisarussell1@nhs.net